AbbVie is acquiring Gilgamesh Pharmaceuticals’ lead drug candidate bretisilocin, used to treat moderate to severe major depressive disorder, for up to $1.2 billion.
Bretisilocin is a psychedelic compound that targets the 5-HT2A receptor and releases serotonin, according to an Aug. 25 news release from AbbVie. It is meant to deliver antidepressant effects with a shorter psychoactive experience compared to other drugs in its class, according to an AbbVie news release.
In a phase 2 trial, a single 10-milligram dose of the drug reduced depressive symptoms by 21.6 points on the Montgomery-Asberg depression rating scale, compared to a 12.1-point reduction for a low-dose comparison.
As part of the deal, Gilgamesh will spin off its remaining programs and staff into a new company that will continue its existing partnership with AbbVie, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
